Pfizer’s Revenue By Region (2016-2022)

This article discusses Pfizer’s Revenue By Region split across the United States, Emerging Markets, Developed Europe, and Developed Rest Of The World from 2016-2021.

Pfizer generates its revenue from the following regions:

• United States
• Emerging Markets
• Developed Europe
• Developed Rest Of The World

Pfizer’s Revenue By Region

(figures in billions, except percentages)

Pfizer’s total revenue increased from $12.03 billion in Q1 2020 to $14.58 billion in Q1 2021, marking an increase of 21.20% on a year-on-year basis. The revenue growth was driven by an increase in sales of medicines like Eliquis, Vyndamax, Xeljanz, Xtandi, and Inlyta. During this period, the company bagged orders for its COVID-19 vaccine from Governments of the United States, United Kingdom, Mexico, Hong Kong, Malaysia, Singapore, and many more.  

Developed Europe

Pfizer’s revenue from Developed Europe rose from $1.92 billion in Q1 2020 to $3.04 billion in Q1 2021, a growth of 58.33% on a year-on-year basis. In Q1 2021, Developed Europe contributed 20.85% to the company’s total revenue.

Developed Europe includes countries from Western Europe like Austria, Belgium, France, Germany, Ireland, Luxembourg. It also includes Scandinavian countries like Denmark, Norway, Sweden, and Finland.

United States

Pfizer’s revenue from the United States increased from $5.65 billion in Q1 2020 to $7.60 billion in Q1 2021, an increase of 34.51% on a year-on-year basis. In Q1 2021, United States contributed 52.13% to Pfizer’s total revenue.

In the US, the company has its manufacturing facilities in Michigan, Kansas, Ohio, New York, Missouri, and North Carolina. Pfizer has a total of 24 offices in different cities of the United States. In the US, the company employs more than 30,000 people. The company’s competitors in this region are Johnson & Johnson, Roche, Novartis, Amgen, Gilead Sciences, and Merck and Co.

In February 2021, the company received orders from the US government for the supply of 100 million doses of the COVID-19 vaccine, bringing the total supply of the COVID-19 vaccine to 300 million to date. The company will receive $1.95 billion for the supply of the COVID-19 vaccine.

Emerging Markets

Pfizer’s revenue from the Emerging Markets declined from $3 billion in Q1 2020 to $2.82 billion in Q1 2021, marking a decline of 6% on a year-on-year basis. In Q1 2021, Emerging Markets contributed 19.34% to Pfizer’s total revenue.

Emerging Markets include regions like Asia (excluding South Korea and Japan), Latin America, Eastern Europe, Central Europe, the Middle East, Turkey, and Africa. 

Developed Rest Of The World

Pfizer’s revenue from this region declined from $1.46 billion in Q1 2020 to $1.12 billion in Q1 2021, marking a decline of 23.29% on a year-on-year basis. In Q1 2021, Developed Rest Of The World contributed 7.68% to the company’s total revenue.

Developed Rest Of The World includes regions like Australia, New Zealand, Canada, Japan, and South Korea.

In May 2021, the Australian Government purchased 20 million doses of the Pfizer-BioNTech COVID-19 vaccine. The company also received orders for its COVID-19 vaccine from the Government of Japan and New Zealand.

Company Overview

Pfizer Inc. is an American bio-pharmaceutical company. The company was founded by Charles Erhart and Charles Pfizer in 1849. Pfizer’s main office is located in New York, United States. Albert Bourla is the current CEO and Chairman of the company. Pfizer manufactures vaccines and medicines for cardiovascular diseases, skin diseases, neurological diseases, cancer, diabetes, and many more.

Pfizer employs more than 78,000 people worldwide. The company has more than 35 manufacturing facilities across 6 continents. 

Over the years, Pfizer has acquired many companies like King Pharmaceuticals, Hospira, Anacor Pharmaceuticals, Bamboo Therapeutics, Medivation, and Array Biopharma with an aim to increase its product portfolio and fight competition. Pfizer faces tough competition from GlaxoSmith Kline, Cipla, Sangamo Therapeutics, Vivus, Takeda Pharmaceuticals, Eli Lilly and Company, and many more.

In March 2020, Pfizer signed an agreement with BioNTech to develop the COVID-19 vaccine. 

Did you like Pfizer’s Revenue By Region statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.